Patients with non–small cell lung cancer who are not eligible for treatment with bevacizumab may benefit from treatment with a combination of nab-paclitaxel and carboplatin, according to phase 2 study results.
Gregory A. Otterson, MD, co-director of the thoracic oncology program at The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J.More »